Alpha Glucosidase Inhibitors Market Analysis 2024 -2033 : Forecasted Market Size, Top Segments, And Largest Region | Pfizer Inc., Roche, Bayer AG, Novartis AG, Sanofi AS, Bristol Myers Squibb Company

"The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2033

The Business Research Company offers in-depth market insights through Alpha Glucosidase Inhibitors Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The alpha glucosidase inhibitors market size has grown strongly in recent years. It will grow from $4.22 billion in 2023 to $4.58 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased incidence of diabetes, growth in awareness of diabetes management, advancements in diabetes treatment strategies, preference for oral antidiabetic medications, clinical research and evidence-based medicine..

The alpha glucosidase inhibitors market size is expected to see strong growth in the next few years. It will grow to $6.11 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growing emphasis on early intervention, rising geriatric population, global healthcare initiatives for diabetes control, integration into combination therapies.. Major trends in the forecast period include patient-centric approaches, focus on type 2 diabetes management, technological advancements in drug delivery, emerging markets and globalization, collaborations and partnerships..

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=11880&type=smp

Market Segmentation:
The alpha glucosidase inhibitors market covered in this report is segmented -

1) By Type: Dumping Syndrome, Type 2 Diabetes
2) By Drug class: Acarbose, Miglitol, Voglibose
3) By Constituent: Glucoamylase, Isomaltase, Maltase, Sucrase
4) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Hospital Pharmacies

Major Driver - Rise In Diabetes Prevalence Fuels Growth Of The Alpha-Glucosidase Inhibitors Market
Rising diabetes prevalence globally is expected to propel the growth of the alpha-glucosidase inhibitors market going forward. Diabetes is a long-term metabolic condition marked by high blood glucose (also known as blood sugar) levels, which can seriously harm the heart, blood vessels, eyes, kidneys, and nerves over time. Alpha-glucosidase inhibitors prevent carbohydrate absorption from the small intestine, which inhibits the rise in postprandial blood glucose concentrations and helps control diabetes. For instance, in November 2022, according to the International Diabetes Federation, a Belgium-based organization for diabetes, globally, 537 million adults (or 1 in 10) had diabetes. Further, the global prevalence of diabetes is expected to increase by 643 million people by 2030 and 783 million people by 2045. Therefore, rising diabetes prevalence globally is driving the growth of the alpha-glucosidase inhibitors market.

Competitive Landscape:
Major companies operating in the alpha glucosidase inhibitors market report are Pfizer Inc., Roche, Bayer AG, Novartis AG, Sanofi AS, Bristol Myers Squibb Company, AstraZeneca Plc., Takeda Pharmaceutical Co. Ltd., Eli Lilly and Company, Novo Nordisk AS, Merck KGaA, Sumitomo Chemical Co.Ltd., C. H. Boehringer Sohn AG and Co. KG, Astellas Pharma, Sun Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Biocon, Torrent Pharmaceuticals, Lotus Pharmaceutical Co. Ltd., Anderson Hay and Grain Co. Inc., BioVision Inc., Border Valley Trading, Straight Healthcare, Synjardi XR

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/alpha-glucosidase-inhibitors-global-market-report

Top Trend - Pioneering Alpha-Glucosidase Inhibitor For Advanced Type 2 Diabetes Management
Product innovation is a key trend gaining popularity in the alpha-glucosidase inhibitors market. Major companies operating in the alpha-glucosidase inhibitors market are developing innovative products to sustain their position in the market. For instance, in January 2023, TheracosBio, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Brenzavvy (bexagliflozin) to treat adults with type 2 diabetes. Brenzavvy is a unique oral inhibitor of sodium-glucose cotransporter 2 (SGLT2). It is suggested as a supplement to diet and exercise to help people with type 2 diabetes better regulate their blood sugar levels by inducing the kidneys to excrete sugar through urine.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Alpha Glucosidase Inhibitors Market Characteristics
3. Alpha Glucosidase Inhibitors Market Trends And Strategies
4. Alpha Glucosidase Inhibitors Market - Macro Economic Scenario
5. Alpha Glucosidase Inhibitors Market Size And Growth
…..
27. Alpha Glucosidase Inhibitors Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.